Concerns are rising about the spread of a new variant of Mpox, referred to as the Clade Ib subclade, which has been detected in DR Congo and several nearby countries, reported New Central, citing AFP. The World Health Organization, or WHO, has stated that it plans to gather a panel of experts to deliberate whether to declare an international emergency, as it did in 2022, the report noted. Shares of Siga Technologies (SIGA), whose lead product is an antiviral drug for the treatment of human smallpox disease, are up 3% in early Wednesday trading. In December 2023, GeoVax Labs (GOVX) announced that it had amended a previously executed Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases to expand GeoVax’s commercial license to include Mpox and smallpox as additional indications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIGA:
- Siga Technologies reports Q2 EPS 3c VS. (4c) last year
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
- SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®
- Siga Technologies announces U.S. government procurement order of $113M
- Eleven Connecticut residents diagnosed with mpox in 2024, Hartford Courant says